Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Choueiri Highlights Advances and Next Steps in RCC

December 18th 2018

Toni K. Choueiri, MD, discusses recent progress in RCC and where future research is heading in the field.

Dr. George on Sequencing in Renal Cell Carcinoma

December 18th 2018

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer

December 18th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Expert Reflects on Recent Pivotal Data in RCC

December 18th 2018

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Dr. Pal on Developments in Frontline Treatments for Patients With mRCC

December 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses developments made in frontline treatment for patients with metastatic renal cell carcinoma (mRCC).

CARMENA Data Leave Unanswered Questions in mRCC

December 14th 2018

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Powles Navigates Rapidly Evolving Frontline Paradigm in Urothelial Carcinoma

December 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Dr. Eber on the Utility of Cytoreductive Nephrectomy in mRCC

December 12th 2018

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses the utility of cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC).

Dr. Choueiri on Next Steps for Treatment in RCC

December 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.

Landmark Trial Puts Robotic Surgery to the Test in Bladder Cancer

December 12th 2018

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Immunotherapy Changes Early-Stage Urothelial Carcinoma Paradigm

December 11th 2018

Newer immunotherapy agents are changing traditional strategies for care, resulting in higher levels of collaboration.

Common Treatment-Related Toxicities in mRCC

December 11th 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).

An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder Cancer

December 10th 2018

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.

Dr. Somer on Immunotherapy Combinations in mRCC

December 8th 2018

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.

Dr. Amin on CheckMate-214 Trial in RCC

December 6th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

December 5th 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

Dr. Choueiri on Frontline Trials of Immunotherapy in RCC

December 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline trials of immunotherapy in renal cell carcinoma.

Dr. George on the Use of Adjuvant Sunitinib in RCC

December 1st 2018

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of adjuvant sunitinib (Sutent) in the treatment of patients with renal cell carcinoma (RCC).

Dr. Powles on the Current State of Research in Bladder Cancer

December 1st 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses the current state of research in bladder cancer.

Dr. Balar on Remaining Questions With Immunotherapy in Bladder Cancer

November 27th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses remaining questions with immunotherapy in bladder cancer.

NEXT PAGE
PREVIOUS PAGE